生命科学资讯

Norgine gets in on Vir's hepatitis D program with €550 European licensing pact

Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay

Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst

Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team

Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B

Medtronic rolls out new peripheral thrombectomy system while making advances in brain bleeds

Nektar claims phase 2 alopecia success after excluding patients who ‘should never have been enrolled’

December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B

Xoma acquires another struggling biotech, this time zeroing in on Generation Bio

Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says

Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drug

Siemens Healthineers taps ALZpath for Alzheimer’s blood test biomarker

MapLight brightens SandboxAQ with new deal to discover new CNS candidates

FDA clears Medivis AR headset platform for neurosurgery navigation

Sanofi signs $1B biobucks pact for Alzheimer’s asset in 2nd biotech deal of the day

Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts

Chai infuses AI drug discovery efforts with $130M series B

J&J-backed Link launches with $60M, plan to create next-gen CAR-T therapies

Aviceda geographic atrophy hopeful fails to top Astellas' med in phase 2

Sanofi's tolebrutinib woes pile up with FDA delay, trial miss